The following joint Editorial was originally published in ACS Applied Materials & Interfaces (DOI: 10.1021/acsami.0c10979). We confront the terrible reality that systemic racism and discrimination impacts the daily personal and professional lives of many members of the scientific community and broader society. In the U.S., the brutal killing of George Floyd while in police custody is one of the most

KRAS, one of the most prevalent oncogenes and sought-after anticancer targets, has eluded chemists for decades until an irreversible covalent strategy targeting a specific mutation (G12C) paved the way for the first KRAS inhibitors to reach the clinic. MRTX849 is one such clinical candidate with promising initial results in patients harboring the mutation. The impressive optimization story of MRTX849

Page 1642. In the left column, line 7, “... leading to the production of the kynurenine derivatives 3-hydroxykynurenine and 3-hydroxyanthranilic acid. These intermediates are kynurenine precursors.” should be corrected to “leading to the production of N-formylkynurenine, a precursor of kynurenine.” Page 1642. In the right column, line 13, “Incyte Corp. reported the cocrystal structure of IDO1/epacadostat”

This article is part of the Artificial Intelligence in Drug Discovery special issue. We are pleased to introduce the Special Issue “Artificial Intelligence in Drug Discovery” highlighting the emerging role of artificial intelligence (AI) in pharmaceutical research. A focal point of this issue is illuminating how AI approaches are beginning to impact the practice of drug discovery. The Special Issue